{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T19:33:07Z","timestamp":1773948787814,"version":"3.50.1"},"reference-count":73,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T00:00:00Z","timestamp":1711065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Malignant pleural mesothelioma (MPM) is a heterogeneous cancer composed of distinct molecular and pathologic subtypes. Unfortunately, MPM is aggressive, and current therapies for advanced, unresectable disease remain limited to cytotoxic chemotherapy and immunotherapy. Our understanding of the genomic landscape of MPM is steadily growing, while the discovery of effective targeted therapies in MPM has advanced more slowly than in other solid tumors. Given the prevalence of alterations in tumor suppressor genes in MPM, it has been challenging to identify actionable targets. However, efforts to characterize the genetic signatures in MPM over the last decade have led to a range of novel targeted therapeutics entering early-phase clinical trials. In this review, we discuss the advancements made thus far in targeted systemic therapies in MPM and the future direction of targeted strategies in patients with advanced MPM.<\/jats:p>","DOI":"10.3390\/cancers16071252","type":"journal-article","created":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T12:28:06Z","timestamp":1711369686000},"page":"1252","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Emerging New Targets in Systemic Therapy for Malignant Pleural Mesothelioma"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1916-2176","authenticated-orcid":false,"given":"Karen M.","family":"Yun","sequence":"first","affiliation":[{"name":"Division of Hematology-Oncology, Moores Cancer Center at UC San Diego Health, La Jolla, CA 92093, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8764-4359","authenticated-orcid":false,"given":"Lyudmila","family":"Bazhenova","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Moores Cancer Center at UC San Diego Health, La Jolla, CA 92093, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"924","DOI":"10.21037\/tlcr.2020.03.38","article-title":"Clinical Significance of Histologic Subtyping of Malignant Pleural Mesothelioma","volume":"9","author":"Brcic","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/carcin\/bgz004","article-title":"Prognostic Factors of Survival in Patients with Malignant Pleural Mesothelioma: An Analysis of the National Cancer Database","volume":"40","author":"Alpert","year":"2019","journal-title":"Carcinogenesis"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1097\/JTO.0b013e3181f1cf2b","article-title":"Malignant Pleural Mesothelioma: A Population-Based Study of Survival","volume":"5","author":"Milano","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-Line Nivolumab plus Ipilimumab in Unresectable Malignant Pleural Mesothelioma (CheckMate 743): A Multicentre, Randomised, Open-Label, Phase 3 Trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1158\/1078-0432.CCR-03-0801","article-title":"Mesothelin: A New Target for Immunotherapy","volume":"10","author":"Hassan","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.lungcan.2009.07.016","article-title":"Inhibition of Mesothelin-CA-125 Interaction in Patients with Mesothelioma by the Anti-Mesothelin Monoclonal Antibody MORAb-009: Implications for Cancer Therapy","volume":"68","author":"Hassan","year":"2010","journal-title":"Lung Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1158\/1078-0432.CCR-11-2614","article-title":"Mesothelin Overexpression Promotes Mesothelioma Cell Invasion and MMP-9 Secretion in an Orthotopic Mouse Model and in Epithelioid Pleural Mesothelioma Patients","volume":"18","author":"Servais","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1128\/MCB.20.8.2902-2906.2000","article-title":"Mesothelin is Not Required for Normal Mouse Development or Reproduction","volume":"20","author":"Bera","year":"2000","journal-title":"Mol. Cell. Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.1158\/1078-0432.CCR-14-0804","article-title":"Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma","volume":"20","author":"Hassan","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4936","DOI":"10.1002\/cncr.33145","article-title":"Phase 1 Study of the Immunotoxin LMB-100 in Patients with Mesothelioma and Other Solid Tumors Expressing Mesothelin","volume":"126","author":"Hassan","year":"2020","journal-title":"Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1158\/2326-6066.CIR-16-0330","article-title":"Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity","volume":"5","author":"Leshem","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"eaaz7252","DOI":"10.1126\/scitranslmed.aaz7252","article-title":"Enhanced Efficacy of Mesothelin-Targeted Immunotoxin LMB-100 and Anti-PD-1 Antibody in Patients with Mesothelioma and Mouse Tumor Models","volume":"12","author":"Jiang","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S1470-2045(22)00061-4","article-title":"Anetumab Ravtansine versus Vinorelbine in Patients with Relapsed, Mesothelin-Positive Malignant Pleural Mesothelioma (ARCS-M): A Randomised, Open-Label Phase 2 Trial","volume":"23","author":"Kindler","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jtho.2023.09.029","article-title":"Phase 1\/2 Randomized Trial of Anetumab Ravtansine and Pembrolizumab Compared to Pembrolizumab for Pleural Mesothelioma\u2014NCT03126630","volume":"18","author":"Mansfield","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.ymthe.2019.07.015","article-title":"Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T-cells Recognizing Mesothelin in Advanced Solid Cancers","volume":"27","author":"Haas","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A Phase I Trial of Regional Mesothelin-Targeted CAR T-Cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti\u2013PD-1 Agent Pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-023-02452-y","article-title":"Mesothelin-Targeting T Cell Receptor Fusion Construct Cell Therapy in Refractory Solid Tumors: Phase 1\/2 Trial Interim Results","volume":"29","author":"Hassan","year":"2023","journal-title":"Nat. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-Cell Therapy in the Era of Solid Tumor Treatment: Current Challenges and Emerging Therapeutic Advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol. Cancer."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T-cells Induce Antitumor Activity in Solid Malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","article-title":"Combination Immunotherapy with CAR T-cells and Checkpoint Blockade for the Treatment of Solid Tumors","volume":"36","author":"Grosser","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2182058","DOI":"10.1080\/2162402X.2023.2182058","article-title":"Mesothelin-Targeting T Cells Bearing a Novel T Cell Receptor Fusion Construct (TRuC) Exhibit Potent Antitumor Efficacy Against Solid Tumors","volume":"12","author":"Ding","year":"2023","journal-title":"Oncoimmunology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1007\/s00262-023-03556-7","article-title":"Functional Enhancement of Mesothelin-Targeted TRuC-T Cells by a PD1-CD28 Chimeric Switch Receptor","volume":"72","author":"McCarthy","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1158\/1538-7445.AM2018-1781","article-title":"HPN536, a T Cell-Engaging, Mesothelin\/CD3-Specific TriTAC for the Treatment of Solid Tumors","volume":"78","author":"Austin","year":"2018","journal-title":"Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1158\/2159-8290.CD-19-1220","article-title":"Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer","volume":"10","author":"Carbone","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_26","first-page":"100231","article-title":"Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy with Germline or Somatic Mutations in BAP1 Gene","volume":"2","author":"Ghafoor","year":"2021","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/emboj.2009.206","article-title":"PARP Is Activated at Stalled Forks to Mediate Mre11-Dependent Replication Restart and Recombination","volume":"28","author":"Bryant","year":"2009","journal-title":"EMBO J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S2213-2600(20)30390-8","article-title":"Rucaparib in Patients with BAP1-Deficient or BRCA1-Deficient Mesothelioma (MiST1): An Open-Label, Single-Arm, Phase 2a Clinical Trial","volume":"9","author":"Fennell","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1158\/1078-0432.CCR-11-0962","article-title":"Polycomb Repressor Complex-2 is a Novel Target for Mesothelioma Therapy","volume":"18","author":"Kemp","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Gan, L., Yang, Y., Li, Q., Feng, Y., Liu, T., and Guo, W. (2018). Epigenetic Regulation of Cancer Progression by EZH2: From Biological Insights to Therapeutic Potential. Biomark. Res., 6.","DOI":"10.1186\/s40364-018-0122-2"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/nm.3947","article-title":"Loss of BAP1 Function Leads to EZH2-Dependent Transformation","volume":"21","author":"LaFave","year":"2015","journal-title":"Nat. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S1470-2045(22)00277-7","article-title":"EZH2 Inhibitor Tazemetostat in Patients with Relapsed or Refractory, BAP1-Inactivated Malignant Pleural Mesothelioma: A Multicentre, Open-Label, Phase 2 Study","volume":"23","author":"Zauderer","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Mola, S., Pinton, G., Erreni, M., Corazzari, M., De Andrea, M., Grolla, A.A., Martini, V., Moro, L., and Porta, C. (2021). Inhibition of the Histone Methyltransferase EZH2 Enhances Protumor Monocyte Recruitment in Human Mesothelioma Spheroids. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094391"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Calvet, L., Dos-Santos, O., Spanakis, E., Jean-Baptiste, V., Le Bail, J.-C., Buzy, A., Paul, P., Henry, C., Valence, S., and Dib, C. (2022). YAP1 Is Essential for Malignant Mesothelioma Tumor Maintenance. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-09686-y"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1158\/1078-0432.CCR-11-2375","article-title":"New Strategies in Pleural Mesothelioma: BAP1 and NF2 as Novel Targets for Therapeutic Development and Risk Assessment","volume":"18","author":"Ladanyi","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Yap, T.A., Kwiatkowski, D.J., Desai, J., Dagogo-Jack, I., Millward, M., Kindler, H., Tolcher, A.W., Frentzas, S., Thurston, A., and Post, L. (2023, January 14\u201319). First-in-Class, First-in-Human Phase 1 Trial of VT3989, an Inhibitor of Yes-Associated Protein (YAP)\/Transcriptional Enhancer Activator Domain (TEAD), in Patients (Pts) with Advanced Solid Tumors Enriched for Malignant Mesothelioma and Other Tumors with Neurofibromatosis 2 (NF2) Mutations. Proceedings of the 2023 AACR Annual Meeting, Orlando, FL, USA.","DOI":"10.1158\/1538-7445.AM2023-CT006"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/modpathol.2015.121","article-title":"The Prognostic Significance of BAP1, NF2, and CDKN2A in Malignant Peritoneal Mesothelioma","volume":"29","author":"Singhi","year":"2016","journal-title":"Mod. Pathol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1038\/onc.2010.614","article-title":"p16Ink4a Overexpression in Cancer: A Tumor Suppressor Gene Associated with Senescence and High-Grade Tumors","volume":"30","author":"Romagosa","year":"2011","journal-title":"Oncogene"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1158\/0008-5472.CAN-05-3907","article-title":"Global Gene Expression Profiling of Pleural Mesotheliomas: Overexpression of Aurora Pinases and P16\/CDKN2A Deletion as Prognostic Factors and Critical Evaluation of Microarray-Based Prognostic Prediction","volume":"66","author":"Chuai","year":"2006","journal-title":"Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00428-008-0689-3","article-title":"Prognostic Significance of P16\/Cdkn2a Loss in Pleural Malignant Mesotheliomas","volume":"453","author":"Dacic","year":"2008","journal-title":"Virchows Arch."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Terenziani, R., Galetti, M., La Monica, S., Fumarola, C., Zoppi, S., Alfieri, R., Digiacomo, G., Cavazzoni, A., Cavallo, D., and Corradi, M. (2022). CDK4\/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells. Cancers, 14.","DOI":"10.3390\/cancers14235925"},{"key":"ref_42","first-page":"2108","article-title":"Homozygous Deletion of CDKN2A and Codeletion of the Methylthioadenosine Phosphorylase Gene in the Majority of Pleural Mesotheliomas","volume":"9","author":"Illei","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/bjc.2013.9","article-title":"The Expression of Axl Receptor Tyrosine Kinase Influences the Tumour Phenotype and Clinical Outcome of Patients with Malignant Pleural Mesothelioma","volume":"108","author":"Pinato","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"8511","DOI":"10.1200\/JCO.2023.41.16_suppl.8511","article-title":"Bemcentinib and Pembrolizumab in Patients with Relapsed Mesothelioma: MIST3, a Phase IIa Trial with Cellular and Molecular Correlates of Efficacy","volume":"41","author":"Krebs","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.1158\/1078-0432.CCR-06-1101","article-title":"In Vivo Loss of Expression of Argininosuccinate Synthetase in Malignant Pleural Mesothelioma Is a Biomarker for Susceptibility to Arginine Depletion","volume":"12","author":"Szlosarek","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jamaoncol.2016.3049","article-title":"Arginine Deprivation with Pegylated Arginine Deiminase in Patients with Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial","volume":"3","author":"Szlosarek","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"CT007","DOI":"10.1158\/1538-7445.AM2023-CT007","article-title":"Phase 2-3 Trial of Pegargiminase plus Chemotherapy versus Placebo plus Chemotherapy in Patients with Non-Epithelioid Pleural Mesothelioma","volume":"83","author":"Szlosarek","year":"2023","journal-title":"Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/onc.2015.125","article-title":"Role of Merlin\/NF2 Inactivation in Tumor Biology","volume":"35","author":"Petrilli","year":"2016","journal-title":"Oncogene"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"S384","DOI":"10.1016\/j.jtho.2023.09.680","article-title":"P2.19-01 First-in-Human Phase 1 Trial of VT3989, a First-in-Class YAP\/TEAD Inhibitor in Patients with Advanced Mesothelioma","volume":"18","author":"Yap","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"LB319","DOI":"10.1158\/1538-7445.AM2023-LB319","article-title":"IAG933, a Selective and Orally Efficacious YAP1\/WWTR1(TAZ)-panTEAD Protein-Protein Interaction Inhibitor with Pre-Clinical Activity in Monotherapy and Combinations","volume":"83","author":"Schmelzle","year":"2023","journal-title":"Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/s41416-021-01547-y","article-title":"Efficacy of CDK4\/6 Inhibitors in Preclinical Models of Malignant Pleural Mesothelioma","volume":"125","author":"Aliagas","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.neo.2017.05.003","article-title":"Combined Inhibition of CDK4\/6 and PI3K\/AKT\/mTOR Pathways Induces a Synergistic Anti-tumor Effect in Malignant Pleural Mesothelioma Cells","volume":"19","author":"Bonelli","year":"2017","journal-title":"Neoplasia"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S1470-2045(22)00062-6","article-title":"Abemaciclib in Patients with p16ink4A-Deficient Mesothelioma (MiST2): A Single-Arm, Open-Label, Phase 2 Trial","volume":"23","author":"Fennell","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1126\/science.aad5214","article-title":"MTAP Deletion Confers Enhanced Dependency on the PRMT5 Arginine Methyltransferase in Cancer Cells","volume":"351","author":"Kryukov","year":"2016","journal-title":"Science"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1158\/1538-7445.AM2022-3941","article-title":"TNG908 Is an MTAPnull-Selective PRMT5 Inhibitor That Drives Tumor Regressions in MTAP-Deleted Xenograft Models across Multiple Histologies","volume":"82","author":"Briggs","year":"2022","journal-title":"Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/2159-8290.CD-23-0669","article-title":"MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer","volume":"13","author":"Engstrom","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12943-019-1090-3","article-title":"AXL Receptor Tyrosine Kinase as a Promising Anti-Cancer Approach: Functions, Molecular Mechanisms and Clinical Applications","volume":"18","author":"Zhu","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/bjc.2016.428","article-title":"Giving AXL the Axe: Targeting AXL in Human Malignancy","volume":"116","author":"Gay","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"104043","DOI":"10.1016\/j.critrevonc.2023.104043","article-title":"Targeting AXL in Mesothelioma: From Functional Characterization to Clinical Implication","volume":"188","author":"Bhadresha","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_60","first-page":"e2300344","article-title":"Targeted Approaches to Treatment of Pleural Mesothelioma: A Review","volume":"7","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive Genomic Analysis of Malignant Pleural Mesothelioma Identifies Recurrent Mutations, Gene Fusions and Splicing Alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_62","first-page":"5242","article-title":"Inhibition of Epidermal Growth Factor Receptor Signaling in Malignant Pleural Mesothelioma","volume":"62","author":"Taffaro","year":"2002","journal-title":"Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1158\/1078-0432.CCR-04-2109","article-title":"Up-regulation of EphB4 in Mesothelioma and its Biological Significance","volume":"11","author":"Xia","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1158\/0008-5472.CAN-04-4567","article-title":"Functional Analysis of c-Met\/Hepatocyte Growth Factor Pathway in Malignant Pleural Mesothelioma","volume":"66","author":"Jagadeeswaran","year":"2006","journal-title":"Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/onc.2010.555","article-title":"AXL Regulates Mesothelioma Proliferation and Invasiveness","volume":"30","author":"Ou","year":"2011","journal-title":"Oncogene"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1200\/JCO.2006.09.7634","article-title":"Phase II Study of Erlotinib in Patients with Malignant Pleural Mesothelioma: A Southwest Oncology Group Study","volume":"25","author":"Garland","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1158\/1078-0432.CCR-04-1940","article-title":"Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B","volume":"11","author":"Govindan","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1158\/1535-7163.MCT-23-0138","article-title":"Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells","volume":"23","author":"Hirai","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"32992","DOI":"10.1038\/srep32992","article-title":"PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma","volume":"6","author":"Kanteti","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejca.2021.12.023","article-title":"Malignant Pleural Mesothelioma: Germline Variants in DNA Repair Genes May Steer Tailored Treatment","volume":"163","author":"Sculco","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 Inhibition Triggers Anti-Tumour Immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41571-022-00649-7","article-title":"Immunotherapy Approaches for Malignant Pleural Mesothelioma","volume":"19","author":"Fennell","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/s41416-022-01979-0","article-title":"Genomic Landscape of Pleural and Peritoneal Mesothelioma Tumours","volume":"127","author":"Hiltbrunner","year":"2022","journal-title":"Br. J. Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/7\/1252\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:18:18Z","timestamp":1760105898000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/7\/1252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,22]]},"references-count":73,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["cancers16071252"],"URL":"https:\/\/doi.org\/10.3390\/cancers16071252","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,22]]}}}